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Abstract Mammographic density is a strong risk factor for
breast cancer, yet the underlying histopathologic correlates
are not clear. Matrix metalloproteinases (MMPs) and their
inhibitors (TIMPs) play important roles in multiple stages
of tumorigenesis. This study examined the association
between mammographic density and expression of MMPs
1, 3, 9, and 12 and TIMP3 in benign and malignant breast
tissue of 277 women with mainly Caucasian and Japanese
ancestry. Tissue microarrays with up to 4 benign and 4
malignant cores per woman were stained immunohisto-
chemically and evaluated. Digitized prediagnostic mammo-
grams were assessed for densities using a computer-assisted
method. General linear models adjusted for known con-
founders were applied to estimate mean densities by
staining category. Strong expression of all MMPs was
about twice as frequent in malignant as in benign tissue,
while TIMP3 expression in stromal tissue was higher in
benign than malignant cores. For MMP3 and 9, less than
10% of cores stained positive; thus, they were not further
analyzed. None of the markers showed a statistically
significant association with breast density in the entire
study population and ethnic-specific results were con-
flicting and difficult to explain. Although not statistically
significant, mean density was consistently lower with more
extensive TIMP3 expression in stromal and epithelial
tissue. These findings indicate that the higher breast cancer
risk in women with dense breasts may be influenced by
lower TIMP3 expression. However, future investigations
into activities and ratios of additional proteases and their
inhibitors as well as other pathways, such as inflammation,
are needed.
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Introduction
Breast density, one of the strongest breast cancer risk
factors, refers to the radiographic appearance of the female
breast [1, 2]. Fat, which is radiolucent, appears dark on a
mammogram. Epithelial and stromal tissues, on the other
hand, appear white or radiodense and are collectively
referred to as mammographic density. As stroma is present
in much larger quantities than epithelium [3], it accounts for
most of the radiological density [4, 5]. Despite several
reports on breast density and proliferative lesions of breast
tissue [6, 7], a full understanding of the cellular basis of
breast density and a biological mechanism for the positive
association with breast cancer risk, however, has yet to be
developed.
Growing evidence supports the notions that altered
regulation of extracellular matrix (ECM) contributes to
neoplastic progression and that disruptions in the ECM may
precede epithelial changes [8]. Matrix metalloproteinases
(MMPs), zinc-dependent endopeptidases involved in
J. S. Steude: G. Maskarinec (*): E. Erber: M. Verheus:
B. Y. Hernandez:J. Killeen
Cancer Research Center of Hawaii,
1236 Lauhala Street,
Honolulu, HI 96813, USA
e-mail: gertraud@crch.hawaii.edu
J. M. Cline
Department of Pathology, Wake Forest
University School of Medicine,
Winston-Salem, NC 27157-1070, USA
J. Killeen
Kapiolani Medical Center for Women and Children,
Honolulu, HI, USA
Cancer Microenvironment (2010) 3:57–65
DOI 10.1007/s12307-009-0031-xremodeling of ECM, contribute to all steps of tumor
progression, including promotion, angiogenesis, and meta-
static lesions [9, 10]. A disruption of the balance between
MMPs and their tissue inhibitors has been implicated in
cancer progression [11]. The importance of stromal com-
position in relation to breast density was shown by a
stronger association of mammographic density with stromal
than epithelial composition and higher collagen density and
stronger proteoglycan expression in mammographically
dense tissue [3]. A similar study found greater amounts of
collagen and higher TIMP3 expression in dense breasts
[12].
Our objective was to investigate the association of breast
density with expression of MMPs 1, 3, 9, and 12 and a
tissue inhibitor of MMPs (TIMP3) in breast tissue of
women with different ethnic backgrounds who participated
in a case-control study of breast density [13]. We propose
that MMPs and their inhibitors play a crucial role in breast
density formation through degradation of ECM and
activation of growth factors which may lead to the
associated increased breast cancer risk. We hypothesize
that changes in MMP expression in tumor tissue reflect
activity in benign tissue in the same subjects.
Materials and Methods
Study Population The current study is based on subjects of
the Hawaii component of the Multiethnic Cohort (MEC)
[14] who took part in a nested case-control (NCC) study of
mammographic densities and breast cancer risk [13]. The
MEC study investigates the association between diet and
cancer in 215,251 adult men and women of different ethnic
backgrounds [14]. Participants entered the MEC study in
1993–96 by completing a mail questionnaire asking for
dietary, demographic, anthropometric, and reproductive
information [14]. Additional information on hormone
replacement therapy (HRT), menopausal status, breast
surgery, and mammograms was obtained when subjects
enrolled in the NCC study [13]. Data from the Hawaii
component of the MEC study is linked annually to the
Hawaii Department of Health and the statewide Hawaii
Tumor Registry (HTR) to identify deaths and cancer cases.
The study was approved by the Institutional Review Boards
of the University of Hawaii and Wake Forest University; all
subjects provided informed consent in writing.
We mailed invitations for the pathology study to 430
women out of the 607 cases in the NCC study [15, 16]; 177
women were not contacted because the respective hospitals
were not participating or because the subjects were
deceased at the time of recruitment. Tissue was available
for 279 of 430 women after exclusions for a variety of
reasons (refusals, too ill to participate, did not sign the
consent form, not linked to HTR, tissue blocks not
available from hospital, or not sufficient tissue in tissue
blocks) and after inclusion of 12 deceased women with
tumor blocks in the HTR. Since tissue cores for two women
could not be evaluated, the final number of included
subjects was 277 (Table 1).
Mammographic Density Assessment Mammographic films
of study participants from clinics throughout the State of
Hawaii were retrieved and digitized using a Kodak LS 85
Film Digitizer (Kodak, Rochester, NY) with a pixel size of
260 μm[ 13]. For the pathology study, results of cranio-
caudal views closest to, but before, the date of diagnosis
were selected. Using the Cumulus software developed at
the University of Toronto, Canada [17], the scanned images
for both breasts were assessed for densities by one reader
(GM) who was blinded to case status and time sequence of
mammograms. Films were randomized by subjects and
films within subjects were viewed one after the other
without knowledge of the temporal order [18]. After the
reader determined a threshold for the edge of the breast and
for the dense tissue, the computer calculated the ratio of the
total number of pixels that constituted the breast area and
the dense area. The intraclass correlation coefficients
derived from duplicate readings were 0.96 for the size of
the dense area and 0.97 for percent density [13]. Because of
the high correlation between readings from the right and the
left breast, means were used for the analysis.
Breast Tissue Tissue blocks for this study were retrieved
through the tissue repository of the HTR [15, 16]. Tissue
microarrays (TMA) were prepared according to standard
procedures [19, 20]. In brief, a surgical pathologist (JK)
identified appropriate tissue blocks from a given patient and
prepared a single hematoxylin and eosin (H&E) slide on
which representative areas of malignant and benign tissue
were marked. The H&E slide was aligned with the
corresponding “donor” tissue block and a 0.6 mm cylindri-
cal tissue specimen was taken from the selected area and
transferred to a “recipient” paraffin block using a tissue-
arraying instrument (Beecher Instruments, Sun Prairie, WI).
When available, 4 malignant and 4 benign cores per patient
were placed in one of 6 paraffin blocks. Out of the 2,232
possible (4 malignant and 4 benign samples for 279
women) specimens, 459 cores (20.6%) could not be placed
due to insufficient tissue in the respective block (29.2%
malignant and 70.8% benign samples). Overall, 1,773
(79.4%) tissue samples were successfully placed in the
TMA blocks. Following TMA construction, 5 μm sections
of TMA blocks were sent to Wake Forest University for
immunohistochemical staining with the following markers:
MMP1 (1906-1), MMP3 (1908-1), MMP9 (1939-1),
MMP12 (1906-1; all Epitomics, Inc., Burlingame, CA),
58 J.S. Steude et al.and TIMP3 (CA 0577; Cell Applications, Inc., San Diego,
CA). The basic staining procedure used an avidin-
biotin-alkaline phosphatase method, modified for antigen
retrieval from paraffin-embedded tissue using the procedure
of Shi et al. [21]. A trained pathologist (JMC) reviewed all
stained specimens to confirm tissue type and malignancy
status. The stained slides were scanned by Aperio Scanning
Services (Aperio Technology, Inc., Vista, CA) and the
digital images were evaluated by one of the authors (JSS).
Because the proportion of stained specimens was very
small, stromal staining was dichotomized into no vs. any
stain, while epithelial staining was classified as no, weak,
or strong according to intensity (Fig. 1). We assigned the
values for the highest level of staining for stromal and
epithelial to each subject.
During staining, about 4–8% of cores fell off with
similar proportions across all markers. On average, 3.5
malignant and 2.9 benign cores per women were available
for evaluation. After excluding core sections with equivocal
features, i.e., incomplete core, fatty tissue only, or bad
staining quality, 259 women had at least one benign stromal
and 274 women had at least one malignant stromal
measurement. Yet, measurements for benign epithelial
tissue were only available for 169 women after excluding
cores with connective tissue only.
Statistical Analysis Data management and statistical analy-
sis were performed using the SAS statistical software,
version 9.1 (SAS Institute Inc., Cary, NC). General linear
models were applied to determine the relation between
markers and mammographic densities, while adjusting for
covariates that are known to be associated with breast
density: age at mammogram, body mass index (BMI) as
continuous variable, ethnicity (Hawaiian, Japanese, Cauca-
sian, Other), parity (0–1, 2–3, >3), age at first live birth
(nulliparous, <21, 21–30, >30 years), age at menarche
(<13, 13–14, >14 years), menopausal status at mammo-
gram, HRT use at mammogram (no use, estrogen only,
Variable All women
a Japanese Caucasian
Sample size 277 119 97
Age at mammogram
b 60.2±8.7 60.6±8.5 61.4±8.6
Body mass index (kg/m
2)
b 24.8±4.4 24.3±3.3 24.4±4.7
Family history of breast cancer 42 (15%) 18 (15%) 11 (11%)
Age at menarche
<13 years 154 (56%) 73 (61%) 49 (51%)
13–14 years 97 (35%) 40 (34%) 36 (37%)
>14 years 26 (9%) 6 (5%) 12 (12%)
Number of children
0–1 84 (30%) 32 (27%) 33 (34%)
2–3 139 (50%) 63 (53%) 49 (51%)
>3 54 (20%) 24 (20%) 15 (16%)
Age at first live birth
<21 years 40 (14%) 9 (8%) 15 (16%)
21–30 years 166 (60%) 81 (68%) 56 (58%)
>30 years 22 (8%) 11 (9%) 7 (7%)
N/A 49 (18%) 18 (15%) 19 (20%)
Menopausal status
Pre 75 (27%) 36 (30%) 15 (16%)
Post 202 (73%) 83 (70%) 82 (85%)
Hormone use at mammogram
No use 125 (45%) 50 (42%) 42 (43%)
Estrogen only 83 (30%) 40 (34%) 30 (31%)
Estrogen plus progesterone 69 (24%) 29 (24%) 25 (26%)
Breast density (%) 37.7±23.5 39.7±23.3 35.6±24.0
Tumor stage
In situ 61 (22%) 26 (22%) 24 (25%)
Localized 169 (61%) 74 (62%) 54 (56%)
Regional 36 (13%) 16 (14%) 12 (12%)
Unknown 11 (4%) 3 (3%) 7 (7%)
Table 1 Characteristics of
women in the pathology study
aIncludes Native Hawaiian and
other ethnicities, which are not
shown separately
bMean values are given
Stromal markers and density 59estrogen/progesterone), family history of breast cancer in a
first degree relative (yes, no), and tumor stage (in situ,
localized, regional, unknown). All analyses were conducted
separately for malignant and benign tissue and stratified by
ethnicity.
Results
This analysis included 277 breast cancer cases with primarily
Caucasian (35%) and Japanese (43%) ancestry (Table 1). The
mean age at mammogram was 60.2±8.7 years. More than
two-thirds of the participants were postmenopausal. Nearly
all women in our study had early-stage disease consisting of
carcinoma in situ (22%) or localized invasive carcinoma
(61%). The mean percent breast density in the study
population was 37.7±23.5%. As expected, density was
inversely associated with age (p=0.001), menopausal status
(p=0.001), BMI (p<0.0001), and parity (p=0.002), whereas
a later age at first live birth (p=0.007) and HRT use
(p=0.002) were related to higher density.
Positive staining of MMP3 and MMP9 was observed in
less than 5% of stromal and less than 20% of epithelial
specimens (Table 2). Therefore, we did not analyze their
relation to breast density any further. In both stromal and
epithelial tissue, MMP1 and MMP12 expression was higher
in malignant than in benign tissue. In stromal tissue, the
proportion of positive stained cells was 28% (malignant)
and 20% (benign) for MMP1 (p<0.0001) and 38%
(malignant) and 10% (benign) for MMP12 (p=0.0004). In
epithelial tissue, the percentages of strongly positive stained
cells were 52% (malignant) and 36% (benign) for MMP1
(p<0.0001) and 75% (malignant) and 44% (benign) for
MMP12 (p=0.001). In epithelium, expression of TIMP3
was higher in malignant (16% strongly positive) than
benign (8%) tissue (p=0.0001), whereas stromal tissue
expression of TIMP3 was higher in benign (33%) than
malignant (19%) samples (p<0.0001). We observed no
significant difference in staining between Japanese and
Caucasians except for MMP12 in malignant tissue; the
proportion stained was higher for Japanese than Caucasian
women both in stromal (p=0.056) and epithelial tissue
(p=0.03). Only for MMP1 in stromal tissue was HRT use
Representative immunohistochemical staining on breast tissue microarray
A-C: Epithelial staining; A: no stain, B: weak stain, C: strong stain
D-E: Stromal staining; D: no stain, E: any stain
A  B C 
DE
Fig. 1 Examples of stromal and epithelial staining in tissue microarray. Representative immunohistochemical staining on breast tissue microarray.
a–c Epithelial staining; a no stain, b weak stain, c strong stain. d-e Stromal staining; d no stain, e any stain
60 J.S. Steude et al.related to staining (p=0.03 for benign and p=0.01 for
malignant); ever users were less likely to have any staining
than never users.
There was no statistically significant association of
MMP1, MMP12, and TIMP3 with breast density in the
entire study population (Fig. 2). After stratification by
ethnicity, we noted several discrepant associations. In
Japanese women, density was inversely associated with
MMP1 expression (31.5% for any stain vs. 41.3% for no
stain in malignant stromal tissue; p=0.04). The same trend,
though not significant, was observed in epithelium. In
contrast, percent density was higher in Caucasian women
with more extensive MMP1 expression; the respective
values for malignant stromal tissue were 40.7% vs. 32.1%
(p=0.12).
Although not statistically significant, mean percent
density was lower with more extensive TIMP3 expression
both in stromal and in epithelial tissue (Fig. 2). In stromal
tissue, mean density was 40.0 vs. 36.9 (p=0.28) for no vs.
any stain in benign tissue; the respective values for
malignant tissue were 36.0 vs. 35.7 (p=0.73). In benign
epithelial tissue, mean density was 43.9% vs. 31.5% for
no vs. strong stain (p=0.10); the respective values
for malignant epithelial tissue were 39.2% vs. 31.9%
(p=0.18). With one exception (malignant stromal tissue
of Caucasians), the inverse association was consistent
across ethnic groups.
Discussion
This exploratory study detected no significant associations
between mammographic density and expression of MMP1,
MMP12, and TIMP3 in breast tissue. However, we found
TIMP3 to be less expressed in tissue from breast cancer
cases with high than low breast density. Despite its lack of
statistical significance, the consistency of this trend across
ethnic groups and tissue types suggests an inverse associ-
Table 2 Proportion of subjects with positive stains for MMPs and TIMP3 by ethnicity
Tissue type/marker All women Japanese Caucasian
N
a Any
b N Any N Any
Stromal tissue
MMP1 benign 237 20.3 104 21.2 82 18.3
malignant 267 28.1 114 27.2 93 25.8
MMP3 benign 242 0.0 109 0.0 80 0.0
malignant 269 0.0 116 0.0 93 0.0
MMP9 benign 244 0.8 110 0.0 82 0.0
malignant 264 4.9 116 4.3 90 4.4
MMP12 benign 220 10.5 93 9.7 76 13.2
malignant 264 37.5 112 41.1 92 28.3
TIMP3 benign 236 33.1 102 29.4 82 35.4
malignant 269 19.0 117 19.7 93 21.5
N Weak Strong N Weak Strong N Weak Strong
Epithelial tissue
MMP1 benign 153 47.1 35.6 73 50.7 27.4 46 47.8 40.0
malignant 249 35.7 52.2 110 35.5 48.2 82 37.8 52.4
MMP3 benign 167 1.8 0.6 78 0.0 51 3.9 0.0
malignant 253 5.5 2.4 110 6.4 2.7 85 3.5 2.4
MMP9 benign 169 3.6 0.6 75 2.7 0.0 51 3.9 0.0
malignant 249 9.6 8.4 111 9.0 10.8 82 7.3 4.9
MMP12 benign 158 38.6 43.7 73 41.1 35.6 47 36.2 51.1
malignant 256 19.1 75.0 111 18.0 78.4 86 24.4 64.0
TIMP3 benign 146 39.0 8.2 65 35.4 4.6 48 41.7 12.5
malignant 254 46.5 15.8 113 47.8 19.5 85 37.8 14.1
aNumbers differ because losses during staining were not the same for all
bStaining is reported as %. Because the proportion of stained specimens was very small, stromal staining was dichotomized into no vs. any stain;
epithelial staining was classified as no, weak, or strong
Stromal markers and density 61ation that needs to be confirmed in future studies with
additional proteins. Whereas the expression of markers
differed little by ethnicity, MMP1 expression was associa-
ted with higher breast density among Caucasian women but
inversely related to breast density in Japanese women. The
results were analogous in epithelial and stromal tissue as
well as malignant and benign samples (Fig. 2). This
observation may be due to chance or it may indicate
genetic or acquired differences in breast tissue.
Although not entirely consistent, hyperplasia, atypical
hyperplasia, and carcinoma in situ appear to be associated
with higher percent densities in some studies [6, 7, 22].
Stromal tissue  Epithelial tissue 
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Fig. 2 Percent density for MMP1, MMP12, and TIMP3 by tissue type and ethnicity (Adjusted for age at mammogram, BMI, ethnicity, parity, age
at first live birth, age at menarche, menopausal status, hormone use at mammogram, family history of breast cancer, and tumor stage)
62 J.S. Steude et al.Associations of high density with intra- and extralobular
fibrosis [23] as well as higher collagen density [3] have also
been described. To our knowledge, no other studies
examined MMPs and their effect on breast density as of
this date. Contrary to our findings, a study with a very
small sample size found high breast density to be associated
to an increased amount of TIMP3 in tissues surrounding
benign lesions [12]. The authors hypothesized that TIMP3
may influence matrix deposition leading to higher breast
density or that TIMP3 may act through alteration of insulin-
like growth factors that influence cell proliferation. A
possible explanation for the discrepancy of the two studies
is that the balance between MMPs and TIMPs is more
important than just the expression of one protein, but the
expression of other MMPs and TIMPs, in particular MMP2,
MMP9, TIMP1, TIMP2, and their ratios, would be needed
to assess the overall balance.
MMPs are thought to be secreted not only by tumor
cells, but mainly by the surrounding reactive microenvi-
ronment. Host stromal cells such as fibroblasts, endothelial
and also infiltrating inflammatory cells respond to nearby
tumor cells by induction of MMPs [24, 25]. These degrade
the basement membrane and ECM components to a more
“watery” consistence, which is radiographically denser than
fat; this facilitates tumor invasion and formation of
metastases [8, 26]. Thus, MMPs also contribute to early
steps of tumor progression, including tumor promotion and
angiogenesis [9, 10]. As a result of the activity of MMPs,
cell-cell and cell-ECM interactions are altered, new
biologically active ECM molecules are generated, and the
bioavailability and activity of many growth factors and
cytokines is modified. We indeed found stronger expression
of all MMPs in malignant than benign tissue. The MMP1
findings in Caucasian women agree with the hypothesis that
MMPs might contribute to the associated higher breast
cancer risk. However, the opposing findings in Japanese
women are difficult to explain and may be due to the
multiple comparisons since there is little difference in risk
factors by ethnicity (Table 1). To evaluate the role of
MMP1 in more depth, concise staining panels including
TIMP1 are needed.
A disruption in the balance between the MMPs and their
natural inhibitors, TIMPs has been implicated in the
progression of cancer [11]. Overexpression of TIMPs
appears to inhibit primary tumor growth in mice [27, 28]
as well as reduce tumor invasion and metastasis [11, 29,
30]. In the present study, TIMP3 expression was lower in
stromal cells of malignant than benign tissue; however, this
was not the case for epithelial cell expression. One possible
hypothesis would be that the lower TIMP3 expression in
women with high breast density may affect the activity of
growth factors and influence matrix deposition that trans-
lates into altered breast density. If low TIMP expression
leads to greater MMP activity, which in turn may lead to
higher breast density and a greater carcinogenic potential of
breast cells, it may be partially responsible for the increased
breast cancer risk associated with breast density. However,
TIMP3 has other bio-cellular functions, not related to MMP
inhibition, such as induction of apoptosis [11, 31]o r
inhibition of endothelial cell motility and proliferation
[32]. These might also be possible mechanisms leading to
low breast density and its associated breast cancer risk.
As a result of the pilot nature of this project, the low
power seriously limited our ability to draw definite
conclusions. Our choice of markers was based on a
literature review regarding relevant MMPs in breast tissue
and breast cancer, availability of antibodies, and experience
at our institution. MMP1, MMP3, MMP9, and MMP12
were shown to be involved in mammary carcinogenesis
[33, 34]. TIMP3 was selected because a previous report had
detected an association with breast density [12]. However,
the markers in this study represent only part of the proteins
that are needed for a complete evaluation of MMP and
TIMP activity. Therefore, one major limitation of our study
is the incompleteness of MMP panels. In particular, the low
staining results of MMP9 and MMP3 might be due to high
levels of TIMP1, their natural inhibitor, which needs to be
assessed in future studies for a thorough understanding of
their interactions. Bias due to intratumor heterogeneity may
have been introduced when sections for the construction of
TMAs were selected because we did not distinguish
between specific areas of the tumor, i.e., center versus
periphery or depth of invasion. The limited response rate,
unavailability of tissue, and the loss of tissue cores may have
led to selection bias. We also acknowledge that the so-called
benign breast tissue was obtained from tumor blocks of
women diagnosed with breast cancer. Therefore, these
samples may not be equivalent to breast tissue from women
with no clinical or mammographic abnormalities. To mini-
mize the risk of misclassification, we reassessed the histopa-
thologyinindividualsectionsontheTMAsafterstainingasto
ensure that malignancy status had been assigned correctly.
On the other hand, this study had several strengths. Our
population included pathologic specimens for ethnically
diverse breast cancer cases from a population-based tissue
repository, a relatively new research approach [19]. The
availability of many demographic and reproductive varia-
bles in a study of tissue characteristics provided us with the
opportunity for statistical adjustments. Furthermore, we
obtained mammograms before the participants were diag-
nosed with breast cancer, which gives us the opportunity to
assess density on mammograms without confounding by
tumor masses. This study benefited from the use of a high
throughput TMA approach which enabled us to stain large
numbers of samples under comparative conditions without
depletion of the tissue block for further research. The
Stromal markers and density 63investigation adds to the limited literature of using TMAs in
epidemiologic studies and to the variety of markers
measured in TMAs [35, 36]. To our knowledge, no
previous studies have examined the association of mam-
mographic density with MMPs. This novel approach
showed trends which might suggest a possible association
of breast density with TIMPs, which might be a step
towards revealing the histopathologic mechanism underly-
ing breast density. However, to fully understand the role of
MMPs and their inhibitors, it is of utmost interest to study
complete panels of MMPs and their inhibitors, in particular
MMP2, MT1-MMP, TIMP1, and TIMP2. Future inves-
tigations into activities and ratios of these proteases as well
as other pathways such as inflammation [37], may lead to
identification of patients at high risk for developing breast
cancer or aggressive tumors [37] and could lead to
innovative breast cancer prevention strategies [26].
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